Beyond the Trial: Treatment Considerations and Sequencing for IDH-Mutant Gliomas

Panelists discuss how early use of IDH inhibitors maximizes therapeutic benefit and address resistance mechanisms, noting that tumors typically develop bypass pathways rather than losing the IDH mutation itself.